INTRODUCTION
Active acromegaly is frequently associated with alterations of glucose metabolism. The prevalence of diabetes mellitus (DM) and impaired glucose tolerance (IGT) in acromegaly ranges in several studies from 19 to 56% and from 16 to 46%, respectively.
The prevalence of reported abnormal glucose metabolism after treatment of acromegaly is more variable (0 to 46% for DM and 0 to 58% for IGT).
The medical treatment of acromegaly may have an impact on glucose metabolism.
AIMS
To study in 57 acromegalic patients the evolution of glucose metabolism from diagnosis until last visit according to disease activity and treatment.
To identify possible risk factors associated with an abnormal glucose tolerance after treatment of acromegaly .
PATIENTS AND METHODS
• Hormonal and metabolic evaluation were performed in all patients at diagnosis and at last follow-up.
• Insulin sensitivity (HOMA-S) and ß-cell function (HOMA-ß) were evaluated by the homeostasis model assessment (HOMA).
• All patients underwent an oral glucose tolerance test (OGTT), with the exception of diabetic patients.
• Categories of glucose tolerance status were defined according to current criteria of the American Diabetes Association (ADA):
The NFG/NGT group had a normal fasting glucose (NFG; < 100 mg/dl) and a normal glucose tolerance (NGT; 2h-post glucose load < 140 mg/dl). 43.3 ± ± ± ±12.7 38.2 ± ± ± ± 10.1 49.7 ± ± ± ± 12.5 $ 46.9 ± ± ± ± 13.9 $ <0.05 Sex ratio H/F 31/26 17/11 5/10 9/5 NS BMI (kg/m²) 27.6 26.7 ± ± ± ± 4.9 26.6 ± ± ± ± 4.6 30.5 ± ± ± ± 3. 17.6 ± ± ± ±10.6 14.9 ± ± ± ± 7.3 14.7 ± ± ± ± 10.0 29.0 ± ± ± ± 11.9 * <0.001 HbA1c (%) 6.5 ± ± ± ±1.7 5.5 ± ± ± ± 0.4 5.9 ± ± ± ± 0.4 7.8 ± ± ± ± 2. • The change in fasting glucose was positively correlated with the change in IGF-I z-score 
The

CONCLUSIONS
• This study shows that more than 50% of acromegalic patients have still IGT or diabetes after treatment and at distance from diagnosis.
• Improvement of glucose metabolism is mainly observed in cured patients and in patients treated with pegvisomant.
• • Fasting glucose decreased in cured patients while it increased in the two other groups.
• Insulin sensitivity (HOMA-S) improved in all patients (but less in active disease) while beta-cell function (HOMA-β) was mostly decreased in controlled patients under medical treatment. • NGT patients were younger and had a higher HOMA-β than IFG/IGT and DM patients.
HOMA-S (%)
• Acromegalic patients had a reduced insulin sensitivity which was more severe in DM patients
• Overweight, hypertension and positive family history of diabetes were more frequent in DM patients compared to NGT patients.
* at last visit. § § § § NGT or IFG/IGT and DM
• Fasting glucose and HbA1c were lower in cured patients than in the two other groups.
• HOMA-S was not significantly different according to disease activity while HOMA-β was lower in controlled patients compared to cured patients.
At last visit All patients
Cured Controlled Active p (n=57) (n=20) (n=28) (n=9) Age (years) 52.2 ± ± ± ±12.4 48.0 ± ± ± ± 12.8 53.5 ± ± ± ± 11.6 57.0 ± ± ± ± 12.7 NS IGF-I z-score 1.2 ± ± ± ±1.2 0.8 ± ± ± ± 1.0 0.9 ± ± ± ± 0.9 2.9 ± ± ± ± 0.6 *, $ <0.001 N patients NGT/IGT/DM 24/15/18 14/2/4 7/11/10 3/2/4 <0.05 ∆ Age (years) +8.8± ± ± ±6.8 +7.8 ± ± ± ± 6.2 +10.1 ± ± ± ± 7.6 +6.9 ± ± ± ± 5.1 NS ∆ BMI (Kg/m²) +1.2 ± ± ± ±2.7 +0.8 ± ± ± ± 2.6 +1.0 ± ± ± ± 2.8 +2.7 ± ± ± ± 2.1 NS ∆ IGF-I z-score -3.6 ± ± ± ±1.8 -4.3 ± ± ± ± 1.5 -3.6 ± ± ± ± 1.9 -2.2 ± ± ± ± 1.5 
